Statements included in this press release that are not a description of historical facts are forward-looking statements, including, without limitation, statements related to future roles and contributions of Mr. Sirota at Optimer. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "seek," "potential," "maximize," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to continue driving adoption and use of DIFICID, the effects of changes in Optimer's management, the outcome of Optimer's review of strategic alternatives including a possible sale of the Company, the potential for lawsuits and enforcement proceedings related to the previously disclosed investigations by U.S. authorities and other risks detailed in Optimer's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.
ContactsOptimer Pharmaceuticals, Inc. David Walsey, Vice President, Investor Relations and Corporate Communications(858) 964-3418
Canale Communications Jason I. Spark, Senior Vice President(619) 849-6005SOURCE Optimer Pharmaceuticals